nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezetimibe—ABCG2—Vismodegib—skin cancer	0.129	0.172	CbGbCtD
Ezetimibe—ABCC3—Fluorouracil—skin cancer	0.112	0.149	CbGbCtD
Ezetimibe—ABCG2—Vemurafenib—skin cancer	0.102	0.136	CbGbCtD
Ezetimibe—ABCG2—Dactinomycin—skin cancer	0.0678	0.0903	CbGbCtD
Ezetimibe—ABCB1—Vismodegib—skin cancer	0.0465	0.0619	CbGbCtD
Ezetimibe—ABCG2—Fluorouracil—skin cancer	0.0458	0.061	CbGbCtD
Ezetimibe—CYP3A4—Temozolomide—skin cancer	0.0402	0.0535	CbGbCtD
Ezetimibe—CYP3A4—Imiquimod—skin cancer	0.0402	0.0535	CbGbCtD
Ezetimibe—ABCC2—Docetaxel—skin cancer	0.0387	0.0515	CbGbCtD
Ezetimibe—ABCG2—Docetaxel—skin cancer	0.035	0.0466	CbGbCtD
Ezetimibe—CYP3A4—Vismodegib—skin cancer	0.0279	0.0371	CbGbCtD
Ezetimibe—ABCB1—Dactinomycin—skin cancer	0.0244	0.0325	CbGbCtD
Ezetimibe—CYP3A4—Vemurafenib—skin cancer	0.022	0.0293	CbGbCtD
Ezetimibe—ABCB1—Docetaxel—skin cancer	0.0126	0.0168	CbGbCtD
Ezetimibe—CYP3A4—Docetaxel—skin cancer	0.00756	0.0101	CbGbCtD
Ezetimibe—SOAT1—hair follicle—skin cancer	0.00426	0.113	CbGeAlD
Ezetimibe—SOAT1—nipple—skin cancer	0.00289	0.0764	CbGeAlD
Ezetimibe—ANPEP—nipple—skin cancer	0.00276	0.0731	CbGeAlD
Ezetimibe—SOAT1—connective tissue—skin cancer	0.00205	0.0542	CbGeAlD
Ezetimibe—ANPEP—connective tissue—skin cancer	0.00196	0.0518	CbGeAlD
Ezetimibe—ANPEP—epithelium—skin cancer	0.00186	0.0492	CbGeAlD
Ezetimibe—ANPEP—skin of body—skin cancer	0.00177	0.0468	CbGeAlD
Ezetimibe—SOAT1—mammalian vulva—skin cancer	0.00169	0.0446	CbGeAlD
Ezetimibe—UGT2B15—female reproductive system—skin cancer	0.00168	0.0444	CbGeAlD
Ezetimibe—ANPEP—mammalian vulva—skin cancer	0.00161	0.0427	CbGeAlD
Ezetimibe—SOAT1—female reproductive system—skin cancer	0.00144	0.0382	CbGeAlD
Ezetimibe—ANPEP—lymphoid tissue—skin cancer	0.00143	0.0379	CbGeAlD
Ezetimibe—ANPEP—female reproductive system—skin cancer	0.00138	0.0365	CbGeAlD
Ezetimibe—SOAT1—head—skin cancer	0.00121	0.0319	CbGeAlD
Ezetimibe—ANPEP—head—skin cancer	0.00115	0.0305	CbGeAlD
Ezetimibe—UGT2B7—female reproductive system—skin cancer	0.00103	0.0271	CbGeAlD
Ezetimibe—SOAT1—lymph node—skin cancer	0.000845	0.0224	CbGeAlD
Ezetimibe—ANPEP—lymph node—skin cancer	0.000808	0.0214	CbGeAlD
Ezetimibe—SLCO1B1—female reproductive system—skin cancer	0.000725	0.0192	CbGeAlD
Ezetimibe—ABCC3—female reproductive system—skin cancer	0.000688	0.0182	CbGeAlD
Ezetimibe—ABCC3—head—skin cancer	0.000575	0.0152	CbGeAlD
Ezetimibe—ABCC2—female reproductive system—skin cancer	0.00055	0.0146	CbGeAlD
Ezetimibe—ABCB1—blood vessel—skin cancer	0.000547	0.0145	CbGeAlD
Ezetimibe—Hepatic failure—Docetaxel—skin cancer	0.000474	0.00224	CcSEcCtD
Ezetimibe—Paraesthesia—Imiquimod—skin cancer	0.000472	0.00223	CcSEcCtD
Ezetimibe—ABCG2—mammalian vulva—skin cancer	0.000468	0.0124	CbGeAlD
Ezetimibe—Dyspnoea—Imiquimod—skin cancer	0.000468	0.00222	CcSEcCtD
Ezetimibe—Hepatobiliary disease—Temozolomide—skin cancer	0.000467	0.00221	CcSEcCtD
Ezetimibe—Photosensitivity reaction—Fluorouracil—skin cancer	0.000465	0.0022	CcSEcCtD
Ezetimibe—Alopecia—Bleomycin—skin cancer	0.000464	0.0022	CcSEcCtD
Ezetimibe—Erythema multiforme—Dactinomycin—skin cancer	0.000463	0.00219	CcSEcCtD
Ezetimibe—Sinusitis—Temozolomide—skin cancer	0.000463	0.00219	CcSEcCtD
Ezetimibe—Dyspepsia—Imiquimod—skin cancer	0.000462	0.00219	CcSEcCtD
Ezetimibe—Erythema—Bleomycin—skin cancer	0.000457	0.00216	CcSEcCtD
Ezetimibe—Decreased appetite—Imiquimod—skin cancer	0.000456	0.00216	CcSEcCtD
Ezetimibe—Hot flush—Docetaxel—skin cancer	0.000455	0.00215	CcSEcCtD
Ezetimibe—Infestation NOS—Fluorouracil—skin cancer	0.000455	0.00215	CcSEcCtD
Ezetimibe—Infestation—Fluorouracil—skin cancer	0.000455	0.00215	CcSEcCtD
Ezetimibe—Flushing—Dactinomycin—skin cancer	0.000454	0.00215	CcSEcCtD
Ezetimibe—Hypersensitivity—Vemurafenib—skin cancer	0.000454	0.00215	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Imiquimod—skin cancer	0.000453	0.00215	CcSEcCtD
Ezetimibe—Fatigue—Imiquimod—skin cancer	0.000453	0.00214	CcSEcCtD
Ezetimibe—Menopausal symptoms—Docetaxel—skin cancer	0.000451	0.00214	CcSEcCtD
Ezetimibe—Pain—Imiquimod—skin cancer	0.000449	0.00213	CcSEcCtD
Ezetimibe—Neuropathy peripheral—Fluorouracil—skin cancer	0.000446	0.00211	CcSEcCtD
Ezetimibe—Hepatitis—Temozolomide—skin cancer	0.000443	0.0021	CcSEcCtD
Ezetimibe—Asthenia—Vemurafenib—skin cancer	0.000442	0.00209	CcSEcCtD
Ezetimibe—Pharyngitis—Temozolomide—skin cancer	0.00044	0.00208	CcSEcCtD
Ezetimibe—Oedema peripheral—Temozolomide—skin cancer	0.000436	0.00207	CcSEcCtD
Ezetimibe—Pruritus—Vemurafenib—skin cancer	0.000436	0.00206	CcSEcCtD
Ezetimibe—Connective tissue disorder—Temozolomide—skin cancer	0.000435	0.00206	CcSEcCtD
Ezetimibe—Alopecia—Dactinomycin—skin cancer	0.000433	0.00205	CcSEcCtD
Ezetimibe—Feeling abnormal—Imiquimod—skin cancer	0.000433	0.00205	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Imiquimod—skin cancer	0.000429	0.00203	CcSEcCtD
Ezetimibe—Sinusitis—Fluorouracil—skin cancer	0.000426	0.00202	CcSEcCtD
Ezetimibe—Erythema—Dactinomycin—skin cancer	0.000426	0.00202	CcSEcCtD
Ezetimibe—Pain in extremity—Docetaxel—skin cancer	0.000426	0.00202	CcSEcCtD
Ezetimibe—Ill-defined disorder—Bleomycin—skin cancer	0.000424	0.00201	CcSEcCtD
Ezetimibe—Anaemia—Bleomycin—skin cancer	0.000422	0.002	CcSEcCtD
Ezetimibe—Diarrhoea—Vemurafenib—skin cancer	0.000421	0.00199	CcSEcCtD
Ezetimibe—Erythema multiforme—Temozolomide—skin cancer	0.000419	0.00198	CcSEcCtD
Ezetimibe—Urticaria—Imiquimod—skin cancer	0.000417	0.00197	CcSEcCtD
Ezetimibe—Abdominal pain—Imiquimod—skin cancer	0.000415	0.00196	CcSEcCtD
Ezetimibe—Body temperature increased—Imiquimod—skin cancer	0.000415	0.00196	CcSEcCtD
Ezetimibe—Malaise—Bleomycin—skin cancer	0.000412	0.00195	CcSEcCtD
Ezetimibe—Flushing—Temozolomide—skin cancer	0.000411	0.00195	CcSEcCtD
Ezetimibe—Dizziness—Vemurafenib—skin cancer	0.000407	0.00193	CcSEcCtD
Ezetimibe—Pharyngitis—Fluorouracil—skin cancer	0.000405	0.00192	CcSEcCtD
Ezetimibe—ABCC3—lymph node—skin cancer	0.000403	0.0107	CbGeAlD
Ezetimibe—Angiopathy—Temozolomide—skin cancer	0.000402	0.0019	CcSEcCtD
Ezetimibe—Immune system disorder—Temozolomide—skin cancer	0.0004	0.00189	CcSEcCtD
Ezetimibe—Mediastinal disorder—Temozolomide—skin cancer	0.000399	0.00189	CcSEcCtD
Ezetimibe—Cough—Bleomycin—skin cancer	0.000399	0.00189	CcSEcCtD
Ezetimibe—Ill-defined disorder—Dactinomycin—skin cancer	0.000396	0.00187	CcSEcCtD
Ezetimibe—Anaemia—Dactinomycin—skin cancer	0.000394	0.00187	CcSEcCtD
Ezetimibe—Liver function test abnormal—Docetaxel—skin cancer	0.000393	0.00186	CcSEcCtD
Ezetimibe—Vomiting—Vemurafenib—skin cancer	0.000391	0.00185	CcSEcCtD
Ezetimibe—Alopecia—Temozolomide—skin cancer	0.000391	0.00185	CcSEcCtD
Ezetimibe—Myalgia—Bleomycin—skin cancer	0.000389	0.00184	CcSEcCtD
Ezetimibe—Chest pain—Bleomycin—skin cancer	0.000389	0.00184	CcSEcCtD
Ezetimibe—Rash—Vemurafenib—skin cancer	0.000388	0.00184	CcSEcCtD
Ezetimibe—Mental disorder—Temozolomide—skin cancer	0.000388	0.00184	CcSEcCtD
Ezetimibe—Dermatitis—Vemurafenib—skin cancer	0.000388	0.00184	CcSEcCtD
Ezetimibe—Hypersensitivity—Imiquimod—skin cancer	0.000387	0.00183	CcSEcCtD
Ezetimibe—Headache—Vemurafenib—skin cancer	0.000386	0.00183	CcSEcCtD
Ezetimibe—Malnutrition—Temozolomide—skin cancer	0.000386	0.00183	CcSEcCtD
Ezetimibe—Erythema—Temozolomide—skin cancer	0.000386	0.00183	CcSEcCtD
Ezetimibe—Breast disorder—Docetaxel—skin cancer	0.000385	0.00182	CcSEcCtD
Ezetimibe—Discomfort—Bleomycin—skin cancer	0.000384	0.00182	CcSEcCtD
Ezetimibe—Malaise—Dactinomycin—skin cancer	0.000384	0.00182	CcSEcCtD
Ezetimibe—Cramp muscle—Docetaxel—skin cancer	0.000383	0.00181	CcSEcCtD
Ezetimibe—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000383	0.00181	CcSEcCtD
Ezetimibe—Nasopharyngitis—Docetaxel—skin cancer	0.000381	0.0018	CcSEcCtD
Ezetimibe—Asthenia—Imiquimod—skin cancer	0.000377	0.00178	CcSEcCtD
Ezetimibe—Confusional state—Bleomycin—skin cancer	0.000376	0.00178	CcSEcCtD
Ezetimibe—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000376	0.00178	CcSEcCtD
Ezetimibe—Anaphylactic shock—Bleomycin—skin cancer	0.000373	0.00177	CcSEcCtD
Ezetimibe—Back pain—Temozolomide—skin cancer	0.000373	0.00177	CcSEcCtD
Ezetimibe—Pruritus—Imiquimod—skin cancer	0.000372	0.00176	CcSEcCtD
Ezetimibe—Infection—Bleomycin—skin cancer	0.000371	0.00175	CcSEcCtD
Ezetimibe—Nausea—Vemurafenib—skin cancer	0.000366	0.00173	CcSEcCtD
Ezetimibe—Thrombocytopenia—Bleomycin—skin cancer	0.000365	0.00173	CcSEcCtD
Ezetimibe—Myalgia—Dactinomycin—skin cancer	0.000363	0.00172	CcSEcCtD
Ezetimibe—Alopecia—Fluorouracil—skin cancer	0.000361	0.00171	CcSEcCtD
Ezetimibe—Diarrhoea—Imiquimod—skin cancer	0.000359	0.0017	CcSEcCtD
Ezetimibe—Discomfort—Dactinomycin—skin cancer	0.000359	0.0017	CcSEcCtD
Ezetimibe—Ill-defined disorder—Temozolomide—skin cancer	0.000358	0.00169	CcSEcCtD
Ezetimibe—Anaemia—Temozolomide—skin cancer	0.000356	0.00169	CcSEcCtD
Ezetimibe—Erythema—Fluorouracil—skin cancer	0.000355	0.00168	CcSEcCtD
Ezetimibe—Angioedema—Temozolomide—skin cancer	0.000352	0.00167	CcSEcCtD
Ezetimibe—Malaise—Temozolomide—skin cancer	0.000348	0.00165	CcSEcCtD
Ezetimibe—Dizziness—Imiquimod—skin cancer	0.000347	0.00164	CcSEcCtD
Ezetimibe—Infection—Dactinomycin—skin cancer	0.000346	0.00164	CcSEcCtD
Ezetimibe—Palpitations—Temozolomide—skin cancer	0.000341	0.00161	CcSEcCtD
Ezetimibe—Thrombocytopenia—Dactinomycin—skin cancer	0.000341	0.00161	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00034	0.00161	CcSEcCtD
Ezetimibe—Cough—Temozolomide—skin cancer	0.000336	0.00159	CcSEcCtD
Ezetimibe—Paraesthesia—Bleomycin—skin cancer	0.000335	0.00159	CcSEcCtD
Ezetimibe—Vomiting—Imiquimod—skin cancer	0.000334	0.00158	CcSEcCtD
Ezetimibe—Hypertension—Temozolomide—skin cancer	0.000333	0.00158	CcSEcCtD
Ezetimibe—Dyspnoea—Bleomycin—skin cancer	0.000333	0.00157	CcSEcCtD
Ezetimibe—Rash—Imiquimod—skin cancer	0.000331	0.00157	CcSEcCtD
Ezetimibe—Dermatitis—Imiquimod—skin cancer	0.000331	0.00157	CcSEcCtD
Ezetimibe—Headache—Imiquimod—skin cancer	0.000329	0.00156	CcSEcCtD
Ezetimibe—Anaemia—Fluorouracil—skin cancer	0.000328	0.00155	CcSEcCtD
Ezetimibe—Arthralgia—Temozolomide—skin cancer	0.000328	0.00155	CcSEcCtD
Ezetimibe—Myalgia—Temozolomide—skin cancer	0.000328	0.00155	CcSEcCtD
Ezetimibe—Infestation NOS—Docetaxel—skin cancer	0.000328	0.00155	CcSEcCtD
Ezetimibe—Infestation—Docetaxel—skin cancer	0.000328	0.00155	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000326	0.00154	CcSEcCtD
Ezetimibe—Discomfort—Temozolomide—skin cancer	0.000324	0.00154	CcSEcCtD
Ezetimibe—Decreased appetite—Bleomycin—skin cancer	0.000324	0.00154	CcSEcCtD
Ezetimibe—ABCC2—lymph node—skin cancer	0.000322	0.00851	CbGeAlD
Ezetimibe—Neuropathy peripheral—Docetaxel—skin cancer	0.000322	0.00152	CcSEcCtD
Ezetimibe—Dry mouth—Temozolomide—skin cancer	0.000321	0.00152	CcSEcCtD
Ezetimibe—Jaundice—Docetaxel—skin cancer	0.00032	0.00151	CcSEcCtD
Ezetimibe—Pain—Bleomycin—skin cancer	0.000319	0.00151	CcSEcCtD
Ezetimibe—Confusional state—Temozolomide—skin cancer	0.000317	0.0015	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000317	0.0015	CcSEcCtD
Ezetimibe—Anaphylactic shock—Temozolomide—skin cancer	0.000315	0.00149	CcSEcCtD
Ezetimibe—Infection—Temozolomide—skin cancer	0.000313	0.00148	CcSEcCtD
Ezetimibe—Nausea—Imiquimod—skin cancer	0.000312	0.00148	CcSEcCtD
Ezetimibe—Hepatobiliary disease—Docetaxel—skin cancer	0.00031	0.00147	CcSEcCtD
Ezetimibe—Nervous system disorder—Temozolomide—skin cancer	0.000309	0.00146	CcSEcCtD
Ezetimibe—Thrombocytopenia—Temozolomide—skin cancer	0.000308	0.00146	CcSEcCtD
Ezetimibe—Feeling abnormal—Bleomycin—skin cancer	0.000307	0.00146	CcSEcCtD
Ezetimibe—Skin disorder—Temozolomide—skin cancer	0.000306	0.00145	CcSEcCtD
Ezetimibe—Chest pain—Fluorouracil—skin cancer	0.000302	0.00143	CcSEcCtD
Ezetimibe—Myalgia—Fluorouracil—skin cancer	0.000302	0.00143	CcSEcCtD
Ezetimibe—Decreased appetite—Dactinomycin—skin cancer	0.000302	0.00143	CcSEcCtD
Ezetimibe—Fatigue—Dactinomycin—skin cancer	0.0003	0.00142	CcSEcCtD
Ezetimibe—Discomfort—Fluorouracil—skin cancer	0.000299	0.00141	CcSEcCtD
Ezetimibe—Pain—Dactinomycin—skin cancer	0.000298	0.00141	CcSEcCtD
Ezetimibe—Urticaria—Bleomycin—skin cancer	0.000296	0.0014	CcSEcCtD
Ezetimibe—Body temperature increased—Bleomycin—skin cancer	0.000295	0.0014	CcSEcCtD
Ezetimibe—Hepatitis—Docetaxel—skin cancer	0.000295	0.00139	CcSEcCtD
Ezetimibe—Confusional state—Fluorouracil—skin cancer	0.000292	0.00138	CcSEcCtD
Ezetimibe—Pharyngitis—Docetaxel—skin cancer	0.000292	0.00138	CcSEcCtD
Ezetimibe—Oedema peripheral—Docetaxel—skin cancer	0.00029	0.00137	CcSEcCtD
Ezetimibe—Anaphylactic shock—Fluorouracil—skin cancer	0.00029	0.00137	CcSEcCtD
Ezetimibe—Connective tissue disorder—Docetaxel—skin cancer	0.000289	0.00137	CcSEcCtD
Ezetimibe—Infection—Fluorouracil—skin cancer	0.000288	0.00136	CcSEcCtD
Ezetimibe—Feeling abnormal—Dactinomycin—skin cancer	0.000287	0.00136	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000287	0.00136	CcSEcCtD
Ezetimibe—Insomnia—Temozolomide—skin cancer	0.000285	0.00135	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Dactinomycin—skin cancer	0.000284	0.00135	CcSEcCtD
Ezetimibe—Nervous system disorder—Fluorouracil—skin cancer	0.000284	0.00135	CcSEcCtD
Ezetimibe—Thrombocytopenia—Fluorouracil—skin cancer	0.000284	0.00134	CcSEcCtD
Ezetimibe—Paraesthesia—Temozolomide—skin cancer	0.000283	0.00134	CcSEcCtD
Ezetimibe—Dyspnoea—Temozolomide—skin cancer	0.000281	0.00133	CcSEcCtD
Ezetimibe—CYP3A4—female reproductive system—skin cancer	0.000279	0.00739	CbGeAlD
Ezetimibe—Erythema multiforme—Docetaxel—skin cancer	0.000278	0.00132	CcSEcCtD
Ezetimibe—Dyspepsia—Temozolomide—skin cancer	0.000277	0.00131	CcSEcCtD
Ezetimibe—Abdominal pain—Dactinomycin—skin cancer	0.000275	0.0013	CcSEcCtD
Ezetimibe—Body temperature increased—Dactinomycin—skin cancer	0.000275	0.0013	CcSEcCtD
Ezetimibe—Hypersensitivity—Bleomycin—skin cancer	0.000275	0.0013	CcSEcCtD
Ezetimibe—Decreased appetite—Temozolomide—skin cancer	0.000274	0.00129	CcSEcCtD
Ezetimibe—Flushing—Docetaxel—skin cancer	0.000273	0.00129	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Temozolomide—skin cancer	0.000272	0.00129	CcSEcCtD
Ezetimibe—Fatigue—Temozolomide—skin cancer	0.000271	0.00128	CcSEcCtD
Ezetimibe—Pain—Temozolomide—skin cancer	0.000269	0.00127	CcSEcCtD
Ezetimibe—Constipation—Temozolomide—skin cancer	0.000269	0.00127	CcSEcCtD
Ezetimibe—Asthenia—Bleomycin—skin cancer	0.000268	0.00127	CcSEcCtD
Ezetimibe—Angiopathy—Docetaxel—skin cancer	0.000267	0.00126	CcSEcCtD
Ezetimibe—ABCB1—epithelium—skin cancer	0.000266	0.00705	CbGeAlD
Ezetimibe—Immune system disorder—Docetaxel—skin cancer	0.000266	0.00126	CcSEcCtD
Ezetimibe—Mediastinal disorder—Docetaxel—skin cancer	0.000265	0.00126	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000264	0.00125	CcSEcCtD
Ezetimibe—Pruritus—Bleomycin—skin cancer	0.000264	0.00125	CcSEcCtD
Ezetimibe—Insomnia—Fluorouracil—skin cancer	0.000262	0.00124	CcSEcCtD
Ezetimibe—Paraesthesia—Fluorouracil—skin cancer	0.00026	0.00123	CcSEcCtD
Ezetimibe—Alopecia—Docetaxel—skin cancer	0.00026	0.00123	CcSEcCtD
Ezetimibe—Feeling abnormal—Temozolomide—skin cancer	0.000259	0.00123	CcSEcCtD
Ezetimibe—Dyspnoea—Fluorouracil—skin cancer	0.000258	0.00122	CcSEcCtD
Ezetimibe—Mental disorder—Docetaxel—skin cancer	0.000258	0.00122	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Temozolomide—skin cancer	0.000257	0.00122	CcSEcCtD
Ezetimibe—Erythema—Docetaxel—skin cancer	0.000256	0.00121	CcSEcCtD
Ezetimibe—Malnutrition—Docetaxel—skin cancer	0.000256	0.00121	CcSEcCtD
Ezetimibe—Hypersensitivity—Dactinomycin—skin cancer	0.000256	0.00121	CcSEcCtD
Ezetimibe—Dyspepsia—Fluorouracil—skin cancer	0.000255	0.00121	CcSEcCtD
Ezetimibe—Decreased appetite—Fluorouracil—skin cancer	0.000252	0.00119	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00025	0.00118	CcSEcCtD
Ezetimibe—Urticaria—Temozolomide—skin cancer	0.00025	0.00118	CcSEcCtD
Ezetimibe—Asthenia—Dactinomycin—skin cancer	0.00025	0.00118	CcSEcCtD
Ezetimibe—Abdominal pain—Temozolomide—skin cancer	0.000249	0.00118	CcSEcCtD
Ezetimibe—Body temperature increased—Temozolomide—skin cancer	0.000249	0.00118	CcSEcCtD
Ezetimibe—Back pain—Docetaxel—skin cancer	0.000248	0.00117	CcSEcCtD
Ezetimibe—Pain—Fluorouracil—skin cancer	0.000248	0.00117	CcSEcCtD
Ezetimibe—Muscle spasms—Docetaxel—skin cancer	0.000247	0.00117	CcSEcCtD
Ezetimibe—Feeling abnormal—Fluorouracil—skin cancer	0.000239	0.00113	CcSEcCtD
Ezetimibe—Diarrhoea—Dactinomycin—skin cancer	0.000238	0.00113	CcSEcCtD
Ezetimibe—Vomiting—Bleomycin—skin cancer	0.000237	0.00112	CcSEcCtD
Ezetimibe—Anaemia—Docetaxel—skin cancer	0.000237	0.00112	CcSEcCtD
Ezetimibe—Rash—Bleomycin—skin cancer	0.000235	0.00111	CcSEcCtD
Ezetimibe—Dermatitis—Bleomycin—skin cancer	0.000235	0.00111	CcSEcCtD
Ezetimibe—ABCG2—lymph node—skin cancer	0.000235	0.00621	CbGeAlD
Ezetimibe—Hypersensitivity—Temozolomide—skin cancer	0.000232	0.0011	CcSEcCtD
Ezetimibe—ABCB1—mammalian vulva—skin cancer	0.000231	0.00611	CbGeAlD
Ezetimibe—Urticaria—Fluorouracil—skin cancer	0.00023	0.00109	CcSEcCtD
Ezetimibe—Body temperature increased—Fluorouracil—skin cancer	0.000229	0.00108	CcSEcCtD
Ezetimibe—Palpitations—Docetaxel—skin cancer	0.000227	0.00107	CcSEcCtD
Ezetimibe—Asthenia—Temozolomide—skin cancer	0.000226	0.00107	CcSEcCtD
Ezetimibe—Cough—Docetaxel—skin cancer	0.000224	0.00106	CcSEcCtD
Ezetimibe—Pruritus—Temozolomide—skin cancer	0.000223	0.00105	CcSEcCtD
Ezetimibe—Nausea—Bleomycin—skin cancer	0.000222	0.00105	CcSEcCtD
Ezetimibe—Hypertension—Docetaxel—skin cancer	0.000221	0.00105	CcSEcCtD
Ezetimibe—Vomiting—Dactinomycin—skin cancer	0.000221	0.00105	CcSEcCtD
Ezetimibe—Rash—Dactinomycin—skin cancer	0.000219	0.00104	CcSEcCtD
Ezetimibe—Myalgia—Docetaxel—skin cancer	0.000218	0.00103	CcSEcCtD
Ezetimibe—Chest pain—Docetaxel—skin cancer	0.000218	0.00103	CcSEcCtD
Ezetimibe—Arthralgia—Docetaxel—skin cancer	0.000218	0.00103	CcSEcCtD
Ezetimibe—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000217	0.00103	CcSEcCtD
Ezetimibe—Diarrhoea—Temozolomide—skin cancer	0.000215	0.00102	CcSEcCtD
Ezetimibe—Hypersensitivity—Fluorouracil—skin cancer	0.000214	0.00101	CcSEcCtD
Ezetimibe—Dry mouth—Docetaxel—skin cancer	0.000213	0.00101	CcSEcCtD
Ezetimibe—Confusional state—Docetaxel—skin cancer	0.000211	0.000999	CcSEcCtD
Ezetimibe—Anaphylactic shock—Docetaxel—skin cancer	0.000209	0.000991	CcSEcCtD
Ezetimibe—Dizziness—Temozolomide—skin cancer	0.000208	0.000985	CcSEcCtD
Ezetimibe—Infection—Docetaxel—skin cancer	0.000208	0.000984	CcSEcCtD
Ezetimibe—Nausea—Dactinomycin—skin cancer	0.000207	0.000978	CcSEcCtD
Ezetimibe—Nervous system disorder—Docetaxel—skin cancer	0.000205	0.000971	CcSEcCtD
Ezetimibe—Pruritus—Fluorouracil—skin cancer	0.000205	0.000971	CcSEcCtD
Ezetimibe—ABCB1—lymphoid tissue—skin cancer	0.000205	0.00543	CbGeAlD
Ezetimibe—Thrombocytopenia—Docetaxel—skin cancer	0.000205	0.00097	CcSEcCtD
Ezetimibe—Skin disorder—Docetaxel—skin cancer	0.000203	0.000962	CcSEcCtD
Ezetimibe—Vomiting—Temozolomide—skin cancer	0.0002	0.000947	CcSEcCtD
Ezetimibe—Rash—Temozolomide—skin cancer	0.000198	0.000939	CcSEcCtD
Ezetimibe—Diarrhoea—Fluorouracil—skin cancer	0.000198	0.000939	CcSEcCtD
Ezetimibe—Dermatitis—Temozolomide—skin cancer	0.000198	0.000938	CcSEcCtD
Ezetimibe—ABCB1—female reproductive system—skin cancer	0.000198	0.00523	CbGeAlD
Ezetimibe—Headache—Temozolomide—skin cancer	0.000197	0.000933	CcSEcCtD
Ezetimibe—Dizziness—Fluorouracil—skin cancer	0.000192	0.000908	CcSEcCtD
Ezetimibe—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000191	0.000902	CcSEcCtD
Ezetimibe—Insomnia—Docetaxel—skin cancer	0.000189	0.000896	CcSEcCtD
Ezetimibe—Paraesthesia—Docetaxel—skin cancer	0.000188	0.000889	CcSEcCtD
Ezetimibe—Nausea—Temozolomide—skin cancer	0.000187	0.000885	CcSEcCtD
Ezetimibe—Dyspnoea—Docetaxel—skin cancer	0.000187	0.000883	CcSEcCtD
Ezetimibe—Vomiting—Fluorouracil—skin cancer	0.000184	0.000873	CcSEcCtD
Ezetimibe—Dyspepsia—Docetaxel—skin cancer	0.000184	0.000872	CcSEcCtD
Ezetimibe—Rash—Fluorouracil—skin cancer	0.000183	0.000865	CcSEcCtD
Ezetimibe—Dermatitis—Fluorouracil—skin cancer	0.000183	0.000865	CcSEcCtD
Ezetimibe—Decreased appetite—Docetaxel—skin cancer	0.000182	0.000861	CcSEcCtD
Ezetimibe—Headache—Fluorouracil—skin cancer	0.000182	0.00086	CcSEcCtD
Ezetimibe—Gastrointestinal disorder—Docetaxel—skin cancer	0.000181	0.000855	CcSEcCtD
Ezetimibe—Fatigue—Docetaxel—skin cancer	0.00018	0.000854	CcSEcCtD
Ezetimibe—Pain—Docetaxel—skin cancer	0.000179	0.000847	CcSEcCtD
Ezetimibe—Constipation—Docetaxel—skin cancer	0.000179	0.000847	CcSEcCtD
Ezetimibe—Feeling abnormal—Docetaxel—skin cancer	0.000172	0.000816	CcSEcCtD
Ezetimibe—Nausea—Fluorouracil—skin cancer	0.000172	0.000815	CcSEcCtD
Ezetimibe—Gastrointestinal pain—Docetaxel—skin cancer	0.000171	0.00081	CcSEcCtD
Ezetimibe—Abdominal pain—Docetaxel—skin cancer	0.000165	0.000783	CcSEcCtD
Ezetimibe—Body temperature increased—Docetaxel—skin cancer	0.000165	0.000783	CcSEcCtD
Ezetimibe—ABCB1—head—skin cancer	0.000165	0.00437	CbGeAlD
Ezetimibe—Hypersensitivity—Docetaxel—skin cancer	0.000154	0.00073	CcSEcCtD
Ezetimibe—Asthenia—Docetaxel—skin cancer	0.00015	0.000711	CcSEcCtD
Ezetimibe—Pruritus—Docetaxel—skin cancer	0.000148	0.000701	CcSEcCtD
Ezetimibe—Diarrhoea—Docetaxel—skin cancer	0.000143	0.000678	CcSEcCtD
Ezetimibe—Dizziness—Docetaxel—skin cancer	0.000138	0.000655	CcSEcCtD
Ezetimibe—Vomiting—Docetaxel—skin cancer	0.000133	0.00063	CcSEcCtD
Ezetimibe—Rash—Docetaxel—skin cancer	0.000132	0.000625	CcSEcCtD
Ezetimibe—Dermatitis—Docetaxel—skin cancer	0.000132	0.000624	CcSEcCtD
Ezetimibe—Headache—Docetaxel—skin cancer	0.000131	0.000621	CcSEcCtD
Ezetimibe—Nausea—Docetaxel—skin cancer	0.000124	0.000588	CcSEcCtD
Ezetimibe—ABCB1—lymph node—skin cancer	0.000116	0.00306	CbGeAlD
